Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer

Critical review of the association between perineal use of talc powder and risk of ovarian cancer

Over the past four decades, there has been increasing concern that perineal use of talc powder, a commonly used personal care product, might be associ…

PPP2R1A Gene Mutations Improve ATR Inhibitor Drug Effectiveness in Ovarian Clear Cell Cancers

A study in Oncogene shows that PPP2R1A mutations increase sensitivity to ATR inhibitors in ARID1A-mutant ovarian clear cell carcinoma, suggesting a potential biomarker for improved treatment strategies.

Breakthrough ovarian cancer screening results

Dr Leearne Hinch, CEO of INOVIQ (ASX:IIQ), discusses the company’s progress in developing a screening test for ovarian cancer—an area with no currently approved screening options. Dr Hinch explains that screening for ovarian cancer has historically been hindered by low disease prevalence and the absence of a single reliable biomarker. INOVIQ’s test uses proprietary exosome technology and advanced AI-driven algorithms to combine multiple biomarke…

Learnings From Key Clinical Trials in Ovarian Cancer

Experts explore the evolving landscape of ovarian cancer treatment, emphasizing the need for targeted therapies and biomarker-driven approaches.

FDA fast tracks PHST001 as treatment for ovarian cancer

Pheast Therapeutics has received fast track designation from the U.S. Food and Drug Administration (FDA) for PHST001, its candidate treatment for ovarian cancer, a type of gynecological cancer. The FDA designation covers the therapy on its own for advanced platinum-resistant ovarian cancer or combined with chemotherapy for platinum-sensitive ovarian cancer. The designation, designed to speed the development of medications for serious and life-th…